Uncategorized

Madrigal’s Rezdiffra beats estimates; Gilead cuts jobs; Banyan debuts

Published

2 hours ago

on

🚀 Madrigal Pharmaceuticals’ MASH drug beats expectations: The biotech’s Rezdiffra sales came in at $311 million for the first quarter, surpassing analysts’ projections by about $10 million, according to TD Cowen analysts. The Pennsylvania drugmaker …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version